5 Ways to Ensure Equitable COVID-19 Vaccine Distribution
Many companies have claimed successful clinical trials for the Coronavirus Vaccine. While the governments across the world are trying hard to get early access, equitable distribution to one and all should be the priority.
The COVID-19 (Coronavirus) pandemic has had the whole world grappling and drastically transforming life as we know it. Worldwide, the healthcare, pharmaceuticals and biotechnology industrieshave been working day and night for vaccine development and immediate availability. Currently, multiple research teams and clinical firms have come up with many versions of the COVID-19 vaccines. Many of these are in the final leg of the testing and approval process. Thanks to the relentless efforts of the medical and research community, we will soon have the COVID-19 vaccination. But this is only the first hurdle crossed.
To ensure that the resources needed to distribute the COVID-19 vaccine fairly must be achieved soon, starting with careful planning, preparation, and distribution as soon as the safe and effective COVID-19 vaccine becomes available. Worldwide cooperation is also particularly important to ensure that sufficient vaccine is available for equitable use in all countries. Only then will we be able to exploit the full potential of this vaccine to prevent further disease deaths.
What Can We Learn From Past Pandemics
Apart from being a testament for the medical technology evolution, the pandemics of the past (Polio, Small Pox, or Spanish Flu) can also teach us a thing or two in dealing with such crisis. A look at the history of vaccines and its distribution reveals accessibility as the real issue, especially when it needs to reach the majority of the planet's population.
In this article, David Heymann, Executive Director for Communicable Diseases at the World Health Organization states, "In 1988, polio was reported in 125 countries that lacked adequate access to the polio vaccine; by 2005, only four countries had not yet interrupted transmission of the virus.”
TheCOVID-19Vaccine Distribution Roadblocks
Effective distribution is the need of the hour to win this pandemic on a global level. Stock-piling, mass manufacturing, global scale distribution are some of the major roadblocks in front of the governing and health bodies across the world.
Heymann in the NCBI article further states, “In the event of an influenza pandemic, however, access to the vaccine will be extremely limited, particularly in the developing world. The global influenza vaccine manufacturing capacity is limited to the approximately 300 million doses of seasonal influenza vaccine, while the global population is 6.6 billion. These doses are produced and distributed each year, mainly within industrialized countries, in formulations that must track slight changes in this constantly mutating virus. This shortfall—the difference between a capacity of 300 million doses and a population of 6.6 billion—presents a challenge that can only be met through global preparation and action.”
How to address these roadblocks by developing an effective strategy to achieve equitable distribution?
Public and Private Partnerships: As pointed out by Heymann, there’s a huge gap between the vaccine manufacturing capacity and the population that needs it. To address this, independent manufacturers from every part of the world need to come together to create partnerships and strategically expand the manufacturing capacities for mass production. The health and governing bodies also need to offer regulatory and financial aids to assist these manufacturers. Recently, The WHO held a donor conference on May 4, at which a large group of world leaders pledged contributions totalling more than $1.5 billion (1.2 billion euros) to support the vaccine.
Taking Support from the Community: Local communities including, healthcare workers, medical students, and volunteers will be needed to set-up vaccine distribution camps in their locality to ensure that vaccine reaches everyone from every corner of the world.
Strict Global Laws Against Stockpiling: Global governing bodies like The WHO and UN need to come forward and start making strict regulatory laws against unnecessary stockpiling of the vaccine by a small number of financially strong countries. This is to ensure that the vaccine is available where it is most needed and that disadvantaged communities across the world receive their fair share.
Avoid Monetization and Competition: Many leading pharmaceutical companies claim that they are not competing with each other, but are "at this stage" with Coronavirus and say they are working as quickly as possible to develop, expand and distribute the COVID-19 vaccine. This attitude is not only ethical but also highly crucial in saving humanity.
Technology, a facilitator: Last, but not the least, technological advancements such as Artificial Intelligence, Robotics, etc., can prove to be useful in effective vaccine distribution and management. For example, with smart analytical capabilities, AI tools can generate statistical data for millions of people and analyse the containment zone for immediate distribution. These tools can also be deployed to get location wise data to enable effective vaccine management and distribution.
When we stop to think about it, we are shocked by the enormous undertaking that is underway around the world and by what lies ahead to develop the COVID-19 vaccine and distribute it to billions of people. We have a responsibility to distribute this vaccine to the world as quickly as possible so that we do not make any crucial mistakes. If we work together and unite in a global response, we can successfully stop this pandemic.
MARBELLA ROYAL CLINIC in the application of the current regulations on the protection of personal data, informs that the personal data collected through the forms on the Website: https://www.marbellaroyalclinic.com/ are included in the specific automated files of users of the services of MARBELLA ROYAL CLINIC.
The automated collection and processing of personal data are intended to maintain the business relationship and perform information, training, consulting and other activities of MARBELLA ROYAL CLINIC. These data will only be transferred to those entities that are necessary for the sole purpose of fulfilling the above mentioned criteria.
MARBELLA ROYAL CLINIC adopts necessary measures to guarantee the security, integrity and confidentiality of data, following the provisions of Regulation (EU) 2016/679 of the European Parliament and of the Council, of April 27, 2016, regarding the protection of natural persons concerning the processing of personal data and their free movement.
The user may at any time exercise the rights of access, opposition, rectification, cancellation, limitation, and portability recognized in the Regulation (EU). The exercise of these rights can be done by the user himself via email to firstname.lastname@example.org or at the address:
In the case of contract for the goods and services offered through https://www.marbellaroyalclinic.com/ to maintain the contractual relationship, as well as the management, administration, information, provision and improvement of the service.
Sending requested information through the forms provided at https://www.marbellaroyalclinic.com/.
Send newsletters, as well as commercial communications of promotions and/or advertising from https://www.marbellaroyalclinic.com/ and the sector.
We remind you that you can oppose the sending of commercial communications, by any means and at any time, by sending an email to the above address.
The fields of these records are mandatory, making it impossible to carry out the stated purposes if these data are not provided.
How long is the collected personal data kept?
The personal data provided by the user will be kept if the commercial relationship is maintained; or in-case you do not request its deletion and during the period for which legal responsibilities for the services provided may arise.
The processing of your data is carried out with the following legal bases that legitimize it:
1. The request for information and/or the contract for services of MARBELLA ROYAL CLINIC, whose terms and conditions will be made available to you in any case, before any eventual contract.
If you do not provide us with your data or you do so erroneously or incompletely, we will not be able to attend to your request, making it completely impossible to provide you with the requested information or to carry out the contract for services.
The data will not be communicated to any third party outside MARBELLA ROYAL CLINIC, except under legal obligation. Eventually, potential providers or service providers with access to information will have potential access to their data, hired on a commercial basis by MARBELLA ROYAL CLINIC, only after signing a confidentiality contract and ordering treatment. Access will be limited to the data necessary to fulfil the contract for services.
Data collected by users of the services
In cases where the user includes files with personal data on shared hosting servers, MARBELLA ROYAL CLINIC is not responsible for the user's failure to comply with the RGPD.
Data retention Following the LSSI
MARBELLA ROYAL CLINIC informs that, as a provider of data hosting service and according to the provisions of Law 34/2002 of July 11 on Services of the Information Society and Electronic Commerce (LSSI), the clinic retains for a maximum period of 12 months, the essential information to identify the origin of the data stored and the moment in which the provision of the service began. The retention of these data does not affect the secrecy of communications and may only be used in the framework of a criminal investigation or for the safeguarding of public safety, making themselves available to judges and/or courts or the Ministry that so requires. The communication of data to the State Forces and Bodies will be made by following the provisions of the regulations on the protection of personal data.
MARBELLA ROYAL CLINIC is the owner of all copyrights, intellectual and industrial property related to https://www.marbellaroyalclinic.com/ and the services offered therein, as well as the programs necessary for its implementation and related information.
Reproduction, publication and/or non-strictly private use of the contents, total or partial, of the website https://www.marbellaroyalclinic.com/, is not allowed without prior written consent.
The intellectual property of the software
The user must respect the third-party programs made available by MARBELLA ROYAL CLINIC, even if they are free and/or publicly available. MARBELLA ROYAL CLINIC has the necessary exploitation rights and intellectual property of the software.
The user does not acquire any rights or license for the contract for services, on the software necessary for the provision of the service, nor on the technical information for monitoring the service, except for the rights and licenses necessary for the fulfilment of the contract for services and only for the duration of them.
For any action that exceeds the fulfilment of the contract, the user will need written authorization from MARBELLA ROYAL CLINIC, and the user is prohibited from accessing, modifying, viewing the configuration, structure and files of the servers owned by MARBELLA ROYAL CLINIC, failure of this will lead to assuming civil and criminal liability derived from any incident that may occur in servers and security systems as a direct consequence of negligent or malicious action on their part.
The intellectual property of hosted content
The use contrary to the legislation on the intellectual property of the services provided by MARBELLA ROYAL CLINIC and, of:
The use that is contrary to Spanish laws or that infringes the rights of third parties is prohibited.
The publication or transmission of any content that, in the opinion of MARBELLA ROYAL CLINIC, is violent, obscene, abusive, illegal, racial, xenophobic or defamatory.
Cracks, serial numbers of programs or any other content that violates the intellectual property rights of third parties.
The collection and/or use of personal data of other users without their express consent or in contravention of the provisions of Regulation (EU) 2016/679 of the European Parliament and of the Council, of April 27, 2016, regarding the protection of natural persons, concerning the processing of personal data and the free movement of the same. The use of the domain's mail server and email addresses to send mass spam.
The user has full responsibility for the content of its website, the information transmitted and stored, hypertext links, third party claims and legal actions regarding intellectual property, third party rights and protection of minors.
The user is responsible for the laws and regulations in force and the rules that have to do with the operation of the online service, electronic commerce, copyrights, maintenance of public order, as well as universal principles of Internet use.
The user will indemnify MARBELLA ROYAL CLINIC for the expenses generated by the imputation of MARBELLA ROYAL CLINIC in any case, whose responsibility was attributable to the user, including legal defence fees and expenses, even in the case of a non-final judicial decision.
Protection of the information hosted
MARBELLA ROYAL CLINIC makes backup copies of the content hosted on its servers; however, it is not responsible for the loss or accidental deletion of data by users. Likewise, it does not guarantee
the full replacement of the data deleted by users, since the data could have been deleted and/or modified during the time since the last backup.
The services offered, except for the specific backup services, do not include the replacement of the contents kept in the backup copies made by MARBELLA ROYAL CLINIC, when this loss is attributable to the user. In this case, a rate will be determined according to the complexity and volume of the recovery, always with the prior acceptance of the user.
The replacement of deleted data is only included in the price of the service when the loss of content is due to causes attributable to MARBELLA ROYAL CLINIC.
In the application of the LSSI, MARBELLA ROYAL CLINIC will not send advertising or promotional communications by email or other equivalent electronic means of communication that have not previously been requested or expressly authorized by their recipients.
In the case of users with whom there is a prior contractual relationship, MARBELLA ROYAL CLINIC is authorized to send commercial communications regarding products or services of MARBELLA ROYAL CLINIC, which are similar to those initially contracted with the client.
In any case, the user, after proving his identity, may request that no more commercial information be sent to him through the Customer Service channels.